[Antibody-based therapy for brain tumor].
Takasu
Syuntaro
S
Department of Neurosurgery, Nagoya Daini Red Cross Hospital.
Yoshikawa
Kazuhiro
K
Yoshida
Jun
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D066246:ErbB Receptors / Q000276:immunology; D005910:Glioma / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007135:Immunoglobulin Variable Region; D051379:Mice; D011995:Recombination, Genetic; D057127:Single-Chain Antibodies; D019063:Tenascin / Q000276:immunology
D000911:Antibodies, Monoclonal; D007135:Immunoglobulin Variable Region; D057127:Single-Chain Antibodies; D019063:Tenascin; C410723:epidermal growth factor receptor VIII; C429184:single chain Fv fragment M97; D003165:Complement System Proteins; D066246:ErbB Receptors